Are we getting to lipid targets in real life?

Archives of Medical Science

Volumn 6, Issue 5, 2010, Pages 639-641

  Katsiki, Niki ^a,b   Mikhailidis, Dimitri P ^a   Athyros, Vasilis G ^c   Hatzitolios, Apostolos I ^b   Karagiannis, Asterios ^c   Banach, Maciej ^d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; C REACTIVE PROTEIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUING EDUCATION; DIABETES MELLITUS; DRUG DOSE REGIMEN; DYSLIPIDEMIA; EDITORIAL; GENERAL PRACTITIONER; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MEDICAL PRACTICE; MEDICAL SPECIALIST; META ANALYSIS; METABOLIC SYNDROME X; PRACTICE GUIDELINE; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 78349281111     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2010.17073     Document Type: Editorial

References (34)

1. Mark L, Paragh G, Karadi I, et al. Changes in attaining lipid goals by general practitioners and specialists in patients at high cardiovascular risk in Hungary between 2004-2008. Arch Med Sci 2010; 6: 695-700.
2. Athyros VG, Karagiannis A, Hatzitolios AI, et al. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Curr Med Res Opin 2009; 25: 971-80.
3. Athyros VG, Hatzitolios AI, Karagiannis A, et al. Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. Curr Med Res Opin 2009; 25: 1931-40.
4. Karagiannis A, Hatzitolios AI, Athyros VG, et al. Implementation of guidelines for the management of arterial hypertension. The impulsion study. Open Cardiovasc Med J 2009; 3: 26-34.
5. Hatzitolios AI, Athyros VG, Karagiannis A, et al. Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. Int J Cardiol 2009; 134: 322-9.
6. Fras Z, Mikhailidis DP. Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Curr Med Res Opin 2008; 24: 2467-76.
7. Migdalis I, Efthimiadis A, Pappas S, et al. Clinical experience with ezetimibe/simvastatin in a Mediterranean population. Curr Med Res Opin 2009; 25: 2571-6.
8. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-26.
9. Angelopoulos J, Krassakopoulos N, Nathanson R, Boukas S, Sampalis JS. Co-administration of ezetimibe and a statin in management of dyslipidemias: a meta-analysis of clinical trials. Arch Med Sci 2009; 5: 347-63.
10. Kiortsis DN, Filippatos TD, Mikhailidis DP, et al. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007; 195: 7-16.
11. Athyros VG, Mikhailidis DP, Kakafika AI, et al. Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. Curr Drug Targets 2007; 8: 483-8.
12. Wainwright G, Mascitelli L, Goldstein MR. Cholesterol-lowering therapy and cell membranes. Stable plaque at the expense of unstable membranes? Arch Med Sci 2009; 5: 289-95.
13. Tziomalos K, Athyors VG, Karagiannis A, et al. Triglycerides and vascular risk: insights from epidemiological data and interventional studies. Curr Drug Targets 2009; 10: 320-7.
14. Brunzell JD, Davidson M, Furberg C, et al. Lipoprotein management in patients with cardiometabolic risk. Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31: 811-22.
15. Brewer HB Jr. New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines. Clin Cardiol 2003; 26 (Suppl. 3): III19-24.
16. McQueen MJ, Hawken S, Wang X, et al; INTERHEART study investigators. Lipids, lipoproteins anf apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372: 224-33.
17. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins and risk of vascular disease. JAMA 2009; 302: 1993-2000.
18. Sniderman A, Solhpour A. Targeting targets for LDL-lowering therapy: lessons from the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem 2009; 55: 391-3.
19. Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between changes in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009; 338: b92.doi: 10.1136/bmj.b92
20. Ridker PM, Genest J, Boekholdt SM, et al; JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the Jupiter trial. Lancet 2010; 376: 333-9.
21. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010; 375: 1634-9.
22. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-8.
23. Harchaoui KE, Visser ME, Kastelein JJ, et al. Triglycerides and cardiovascular risk. Curr Cardiol Rev 2009; 5: 216-22.
24. Kolovou G, Anagnostopoulou K, Mikhailidis DP. One century of triglycerides, but there is still lots to learn! Curr Drug Targets 2009; 10: 299-301.
25. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009; 15: MS1-5.
26. MHRA 2004. Reclassification summary for simvastatin POM to P. Medicines and Healthcare Products Regulatory Agency at http://medicines.mhra-gov.uk.
27. Royal Pharmaceutical Society of Great Britain, 2004. Practice guidance on sale of over-the-counter simvastatin [online]. Available: http://www.rpsgb.org. uk/pdfs/otcsimvastatinguid.pdf
28. Tinetti ME. Over-the-Counter Sales of Statins and Other Drugs for Asymptomatic Conditions. New Engl J Med 2008; 358: 2728-32.
29. Brass EP, Vassil T, Replogle A, et al. Can consumers self-select for appropriate use of an over-the-counter statin? The Self Evaluation of Lovastatin to Enhance Cholesterol Treatment Study. Am J Cardiol 2008; 101: 1448-50.
30. Gemmel I, Verma A, Harrison RA. Should we encourage over-the-counter statins? A population perspective for coronary heart disease prevention. Am J Cardiovasc Drugs 2007; 7: 299-302.
31. Landini L, Leone A, Mikhailidis DP. Modifying cardiovascular risk factors: newer insights and preventive measures. Curr Pharm Des 2009; 15: 1034-7.
32. Desai RV, Banach M, Ahmed MI, et al. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol 2010; 106: 221-7.
33. Dreiher J, Cohen A, Weitzman S, Sharf A, Shvartzman P. Lipid levels among African and Middle-Eastern Bedouin populations. Med Sci Monit 2008; 14: CR339-344.
34. Tziomalos K, Weerasinghe CN, Mikhailidis DP, Seifalian AM. Vascular risk factors in South Asians. Int J Cardiol 2008; 128: 5-16.